Figure 4. Alpelisib plus fulvestrant in patients with PIK3CA mutation-positive, HR+/HER2– breast cancer that has recurred/progressed on or after aromatase inhibitor therapy: Effect on progression-free survival during SOLAR-1 study, by patient sub-group.#5